Colorectal Cancer Center and Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China; Research Laboratory of Tumor Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-related Molecular Network and National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Research Laboratory of Tumor Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-related Molecular Network and National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Biochim Biophys Acta Mol Basis Dis. 2024 Feb;1870(2):166922. doi: 10.1016/j.bbadis.2023.166922. Epub 2023 Oct 26.
Colorectal cancer (CRC), a prevalent global malignancy, often necessitates adjuvant therapies such as chemotherapy, radiotherapy, targeted therapy, and immunotherapy to mitigate tumor burden in advanced stages. The efficacy of these therapies is significantly influenced by reactive oxygen species (ROS). Previous research underscores the pivotal role of ROS in gut pathology, targeted therapy, and drug resistance. ROS-mediated CRC adjuvant therapies encompass a myriad of mechanisms, including cell death and proliferation, survival and cell cycle, DNA damage, metabolic reprogramming, and angiogenesis. Preliminary clinical trials have begun to unveil the potential of ROS-manipulating therapy in enhancing CRC adjuvant therapies. This review aims to provide a comprehensive synthesis of studies exploring the role of ROS in CRC adjuvant therapies.
结直肠癌（CRC）是一种常见的全球恶性肿瘤，在晚期通常需要辅助治疗，如化疗、放疗、靶向治疗和免疫治疗，以减轻肿瘤负担。这些治疗的疗效受到活性氧（ROS）的显著影响。先前的研究强调了 ROS 在肠道病理学、靶向治疗和耐药性中的关键作用。ROS 介导的 CRC 辅助治疗包括多种机制，包括细胞死亡和增殖、存活和细胞周期、DNA 损伤、代谢重编程和血管生成。初步的临床试验已经开始揭示 ROS 调控治疗在增强 CRC 辅助治疗中的潜力。本综述旨在对探讨 ROS 在 CRC 辅助治疗中的作用的研究进行全面综合。
